Understanding Pembrolizumab-Induced Acalculous Cholecystitis: When Immunotherapy Affects the Gallbladder

The landscape of cancer treatment has been transformed by immune checkpoint inhibitors (ICIs) like pembrolizumab. These therapies work by unleashing the body’s immune system to recognize and attack malignant cells. However, because this process involves systemic immune activation, it can sometimes lead to immune-related adverse events (irAEs) that affect healthy organs.

While clinicians are well-versed in managing common side effects like skin rashes or colitis, emerging reports highlight rare, inflammatory complications involving the gallbladder, specifically acalculous cholecystitis. Understanding these rare occurrences is essential for oncologists and patients alike to ensure timely diagnosis, and intervention.

What Is Acalculous Cholecystitis?

Cholecystitis is the inflammation of the gallbladder. While most cases are caused by gallstones, acalculous cholecystitis occurs in the absence of stones. In the context of immunotherapy, this condition is thought to be an immune-mediated response where the body’s T-cells inadvertently target the gallbladder tissue.

Research published in the Journal for ImmunoTherapy of Cancer identifies that while ICI treatment is highly effective, it can result in a clinical condition similar to typical acute cholecystitis in a minority of patients. Because the symptoms—such as abdominal pain, fever, and nausea—can mimic other gastrointestinal issues, identifying the link to the medication requires a high level of clinical suspicion.

Key Takeaways for Patients and Providers

• Systemic Impact: Immunotherapy can cause inflammation in organs far removed from the primary tumor site, including the gallbladder.
• Mimicry: Pembrolizumab-induced cholecystitis often presents similarly to standard cholecystitis, making it a “great mimic” in clinical settings.
• Early Recognition: Prompt identification of unexplained abdominal pain in patients receiving immunotherapy is vital for preventing severe complications.
• Multidisciplinary Care: Management often involves a team approach between oncologists, gastroenterologists, and surgeons.

Recognizing the Symptoms

Patients undergoing pembrolizumab therapy should be vigilant regarding new or worsening gastrointestinal symptoms. Common indicators of potential gallbladder inflammation include:

• Persistent pain in the upper right quadrant of the abdomen.
• Unexplained fever or chills.
• Nausea and vomiting.
• Tenderness upon physical examination of the abdomen.

If you are currently receiving immunotherapy and experience these symptoms, it is critical to contact your oncology care team immediately. Do not assume that abdominal discomfort is merely a side effect of chemotherapy or a routine digestive issue.

Management and Prognosis

When clinicians suspect immune-mediated cholecystitis, they typically perform imaging studies, such as an ultrasound or CT scan, to rule out gallstones and evaluate the gallbladder wall for signs of inflammation. If an immune-related cause is suspected, treatment strategies often include pausing the immunotherapy and, in some cases, utilizing corticosteroids to dampen the overactive immune response.

In most documented cases, if caught early, the condition is manageable. The goal is to resolve the inflammation while balancing the need to continue cancer treatment. As we continue to refine our use of checkpoint inhibitors, the medical community is becoming better equipped to identify these rare “off-target” effects, ensuring that patients can continue their fight against cancer with the highest level of safety.

Frequently Asked Questions

Is acalculous cholecystitis a common side effect of pembrolizumab?
No, it is considered a rare adverse event. Most patients on immunotherapy do not experience gallbladder inflammation.

Can I continue my cancer treatment if I develop this condition?
This is a clinical decision made by your medical team. Often, treatment is temporarily paused to allow the gallbladder inflammation to resolve, and your doctor will determine the safest path forward based on your specific health profile.

How is this different from regular gallbladder issues?
The primary difference is the cause. Regular cholecystitis is usually triggered by gallstones obstructing the bile duct. Pembrolizumab-induced cholecystitis is an inflammatory condition triggered by the immune system, occurring without the presence of stones.

Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.